ArticleJournal of hematology & oncology2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Article in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.Annals of hematology · 2025Pooled it
- Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.Blood advances · 2026Trial
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.Blood advances · 2026Article
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery · 2026Article
- Dramatic Response to Elranatamab in a Patient with Large PlasmacytomasTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.American journal of hematology · 2026Article
- Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.Blood cancer journal · 2026Article
- Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.British journal of haematology · 2026Article
- CAR T-cell Therapy for Extramedullary Multiple Myeloma: from Early Response to Durable Disease Control.Stem cell reviews and reports · 2026Article
- When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.Cancers · 2026Review
- Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.Bone marrow transplantation · 2026Article
- Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease.Journal of translational medicine · 2026Article
- Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.Journal of hematology & oncology · 2026Article
- Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report.International journal of hematology · 2026Article
- Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.Blood cancer journal · 2026Article
- Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.Blood cancer journal · 2026Article
- Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma.Hematological oncology · 2026Review
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1-6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2-12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1-2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.